Literature DB >> 24768314

Tractography reveals diffuse white matter abnormalities in Myotonic Dystrophy Type 1.

Jeffrey R Wozniak1, Bryon A Mueller2, Kelvin O Lim2, Laura S Hemmy2, John W Day3.   

Abstract

Cerebral involvement in Myotonic Dystrophy Type 1 (DM1) is well-established but not well characterized. This study applied new Diffusion Tensor Imaging (DTI) tractography to characterize white matter disturbance in adults with DM1. Forty-five participants with DM1 and 44 control participants had MRIs on a Siemens 3T TIM Trio scanner. Data were processed with TRActs Constrained by UnderLying Anatomy (TRACULA) and 7 tracts were evaluated. Bilateral disturbances in white matter integrity were seen in all tracts in participants with DM1 compared to controls. There were no right-left hemisphere differences. The resulting DTI metrics were correlated with cognitive functioning, particularly working memory and processing speed. Motor speed was not significantly correlated with white matter microstructural integrity and, thus, was not the core explanation for the working memory and processing speed findings. White matter integrity was correlated with important clinical variables including the muscular impairment rating scale (MIRS). CTG repeat length was moderately associated with white matter status in corticospinal tract and cingulum. Sleepiness (Epworth Sleepiness Scale) was moderately associated with white matter status in the superior longitudinal fasciculus and cingulum. Overall, the results add to an emerging literature showing widespread white matter disturbances in both early-onset and adult-onset DM1. Results suggest that further investigation of white matter pathology is warranted in DM1 and that non-invasive measures such as DTI have a potentially important clinical value in characterizing the status of individuals with DM1.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Brain; Diffusion Tensor Imaging; MRI; Myotonic Dystrophy; Neuropsychology; White matter

Mesh:

Year:  2014        PMID: 24768314      PMCID: PMC4042407          DOI: 10.1016/j.jns.2014.04.005

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  48 in total

1.  Estimation of WAIS-III intelligence from combined performance and demographic variables: development of the OPIE-3.

Authors:  Mike R Schoenberg; James G Scott; Kevin Duff; Russell L Adams
Journal:  Clin Neuropsychol       Date:  2002-12       Impact factor: 3.535

2.  Cerebral and muscle MRI abnormalities in myotonic dystrophy.

Authors:  Daniel T Franc; Ryan L Muetzel; Paul R Robinson; Craig P Rodriguez; Joline C Dalton; Cameron E Naughton; Bryon A Mueller; Jeffrey R Wozniak; Kelvin O Lim; John W Day
Journal:  Neuromuscul Disord       Date:  2012-01-30       Impact factor: 4.296

3.  Report of the first Outcome Measures in Myotonic Dystrophy type 1 (OMMYD-1) international workshop: Clearwater, Florida, November 30, 2011.

Authors:  Cynthia Gagnon; Giovanni Meola; Luc J Hébert; Jack Puymirat; Luc Laberge; Mario Leone
Journal:  Neuromuscul Disord       Date:  2013-09-05       Impact factor: 4.296

4.  Anterior temporal white matter lesions in myotonic dystrophy with intellectual impairment: an MRI and neuropathological study.

Authors:  A Ogata; S Terae; M Fujita; K Tashiro
Journal:  Neuroradiology       Date:  1998-07       Impact factor: 2.804

5.  Cognitive profile in childhood myotonic dystrophy type 1: is there a global impairment?

Authors:  Nathalie Angeard; Marcela Gargiulo; Aurélia Jacquette; Hélène Radvanyi; Bruno Eymard; Delphine Héron
Journal:  Neuromuscul Disord       Date:  2007-04-12       Impact factor: 4.296

6.  Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy.

Authors:  J Mathieu; H Boivin; D Meunier; M Gaudreault; P Bégin
Journal:  Neurology       Date:  2001-02-13       Impact factor: 9.910

7.  Subtle cognitive dysfunction in adult onset myotonic dystrophy type 1 (DM1) and type 2 (DM2).

Authors:  C Gaul; T Schmidt; G Windisch; T Wieser; T Müller; S Vielhaber; S Zierz; B Leplow
Journal:  Neurology       Date:  2006-07-25       Impact factor: 9.910

Review 8.  Cardiovascular manifestations of myotonic dystrophy-1.

Authors:  Ali A Sovari; C Kenneth Bodine; Farhad Farokhi
Journal:  Cardiol Rev       Date:  2007 Jul-Aug       Impact factor: 2.644

9.  A new method for measuring daytime sleepiness: the Epworth sleepiness scale.

Authors:  M W Johns
Journal:  Sleep       Date:  1991-12       Impact factor: 5.849

10.  Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member.

Authors:  J D Brook; M E McCurrach; H G Harley; A J Buckler; D Church; H Aburatani; K Hunter; V P Stanton; J P Thirion; T Hudson
Journal:  Cell       Date:  1992-02-21       Impact factor: 41.582

View more
  28 in total

1.  Methylphenidate Attenuates the Cognitive and Mood Alterations Observed in Mbnl2 Knockout Mice and Reduces Microglia Overexpression.

Authors:  Carla Ramon-Duaso; Thomas Gener; Marta Consegal; Cristina Fernández-Avilés; Juan José Gallego; Laura Castarlenas; Maurice S Swanson; Rafael de la Torre; Rafael Maldonado; M Victoria Puig; Patricia Robledo
Journal:  Cereb Cortex       Date:  2019-07-05       Impact factor: 5.357

2.  RAN Translation Regulated by Muscleblind Proteins in Myotonic Dystrophy Type 2.

Authors:  Tao Zu; John D Cleary; Yuanjing Liu; Monica Bañez-Coronel; Jodi L Bubenik; Fatma Ayhan; Tetsuo Ashizawa; Guangbin Xia; H Brent Clark; Anthony T Yachnis; Maurice S Swanson; Laura P W Ranum
Journal:  Neuron       Date:  2017-09-13       Impact factor: 17.173

3.  MRI findings and cognitive functions in a small cohort of myotonic dystrophy type 1: Retrospective analyses.

Authors:  Arsida Bajrami; Filiz Azman; Vildan Yayla; Sultan Cagirici; Cahit Keskinkiliç; Nejla Sozer
Journal:  Neuroradiol J       Date:  2016-11-11

4.  Brief assessment of cognitive function in myotonic dystrophy: Multicenter longitudinal study using computer-assisted evaluation.

Authors:  Gayle K Deutsch; Katharine A Hagerman; Jacinda Sampson; Gersham Dent; Jeanne Dekdebrun; Dana M Parker; Charles A Thornton; Chad R Heatwole; Sub H Subramony; Ami K Mankodi; Tetsuo Ashizawa; Jeffrey M Statland; W David Arnold; Richard T Moxley; John W Day
Journal:  Muscle Nerve       Date:  2022-02-28       Impact factor: 3.852

Review 5.  Diffusion MRI and its Role in Neuropsychology.

Authors:  Bryon A Mueller; Kelvin O Lim; Laura Hemmy; Jazmin Camchong
Journal:  Neuropsychol Rev       Date:  2015-08-09       Impact factor: 7.444

Review 6.  Myotonic Dystrophy Type 1 Management and Therapeutics.

Authors:  Cheryl A Smith; Laurie Gutmann
Journal:  Curr Treat Options Neurol       Date:  2016-12       Impact factor: 3.598

7.  Cortical and Subcortical Grey and White Matter Atrophy in Myotonic Dystrophies Type 1 and 2 Is Associated with Cognitive Impairment, Depression and Daytime Sleepiness.

Authors:  Christiane Schneider-Gold; Barabara Bellenberg; Christian Prehn; Christos Krogias; Ruth Schneider; Jan Klein; Ralf Gold; Carsten Lukas
Journal:  PLoS One       Date:  2015-06-26       Impact factor: 3.240

8.  Relationship between neuropsychological impairment and grey and white matter changes in adult-onset myotonic dystrophy type 1.

Authors:  Sigrid Baldanzi; Paolo Cecchi; Serena Fabbri; Ilaria Pesaresi; Costanza Simoncini; Corrado Angelini; Ubaldo Bonuccelli; Mirco Cosottini; Gabriele Siciliano
Journal:  Neuroimage Clin       Date:  2016-06-15       Impact factor: 4.881

9.  Cognitive Deficits, Apathy, and Hypersomnolence Represent the Core Brain Symptoms of Adult-Onset Myotonic Dystrophy Type 1.

Authors:  Jacob N Miller; Alison Kruger; David J Moser; Laurie Gutmann; Ellen van der Plas; Timothy R Koscik; Sarah A Cumming; Darren G Monckton; Peggy C Nopoulos
Journal:  Front Neurol       Date:  2021-07-01       Impact factor: 4.003

10.  Relationship of white and gray matter abnormalities to clinical and genetic features in myotonic dystrophy type 1.

Authors:  Stefano Zanigni; Stefania Evangelisti; Maria Pia Giannoccaro; Federico Oppi; Roberto Poda; Antonio Giorgio; Claudia Testa; David Neil Manners; Patrizia Avoni; Laura Ludovica Gramegna; Nicola De Stefano; Raffaele Lodi; Caterina Tonon; Rocco Liguori
Journal:  Neuroimage Clin       Date:  2016-05-03       Impact factor: 4.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.